Novo Nordisk Research Center Gladsaxe ApS - CVR: 39119374

2022, DKK

14.06.2023

Bruttoresultat

379'

Primær drift

-7.803'

Årets resultat

-8.830'

Aktiver

7.777'

Kortfristede aktiver

7.777'

Egenkapital

-5.889'

Afkastningsgrad

-100 %

Soliditetsgrad

-76 %

Likviditetsgrad

170 %

Resultat

14.06.2023

Årsrapport	2022 14.06.2023	2021 13.06.2022	2020 14.06.2021	2019 01.06.2020	2017 28.05.2019
Nettoomsætning
Bruttoresultat	379.438	0	10.676.598	25.623.833	14.947.235
Resultat af primær drift	-7.802.912	-7.384.070	4.076.684	18.553.530	12.601.033
Indtægter af kapitalandele (tilknyttede og associerede)	0	0	0	0	0
Finansielle indtægter	0	1.180	931	2.260	1.199
Finansieringsomkostninger	-2.180.230	-299.029	-159.566	-54.311	-11.869
Andre finansielle omkostninger	0	0	0	0	0
Resultat før skat	-9.983.142	-7.681.919	3.918.049	18.501.479	12.590.363
Resultat	-8.830.214	-6.196.311	3.185.064	14.426.111	9.820.500
Forslag til udbytte	0	0	0	-12.000.000	0

Aktiver

14.06.2023

Årsrapport	2022 14.06.2023	2021 13.06.2022	2020 14.06.2021	2019 01.06.2020	2017 28.05.2019
Kortfristede varebeholdninger	0	0	0	0	0
Kortfristede tilgodehavender fra salg og tjenesteydelser	1.501.193	1.532.057	333.102	207.617	294.139
Likvider	6.276.002	7.639.998	9.160.502	25.247.502	11.051.459
Kortfristede aktiver	7.777.195	9.172.055	9.493.604	25.455.119	11.345.598
Immaterielle aktiver og goodwill	0	0	0	27.778	194.445
Finansielle anlægsaktiver	0	0	0	0	0
Materielle aktiver	0	1.521.173	2.211.409	2.747.673	989.289
Langfristede aktiver	0	1.521.173	2.211.409	2.775.451	1.183.734
Aktiver	7.777.195	10.693.228	11.705.013	28.230.570	12.529.332

Aktiver

14.06.2023

Passiver

14.06.2023

Årsrapport	2022 14.06.2023	2021 13.06.2022	2020 14.06.2021	2019 01.06.2020	2017 28.05.2019
Forslag til udbytte	0	0	0	12.000.000	0
Egenkapital	-5.889.294	2.940.920	9.487.231	18.302.167	9.824.541
Hensatte forpligtelser	0	0	144.064	0	0
Langfristet gæld til banker	0	0	0	0	0
Anden langfristet gæld	488.351	428.631	486.778	170.284	0
Leverandører af varer og tjenesteydelser	353.068	517.119	26.184	122.833	70.050
Kortfristede forpligtelser	4.570.341	1.946.542	1.586.940	9.758.119	2.653.276
Gældsforpligtelser	13.666.489	7.752.308	2.073.718	9.928.403	2.653.276
Forpligtelser	13.666.489	7.752.308	2.073.718	9.928.403	2.653.276
Passiver	7.777.195	10.693.228	11.705.013	28.230.570	12.529.332

Passiver

14.06.2023

Nøgletal

14.06.2023

Årsrapport	2022 14.06.2023	2021 13.06.2022	2020 14.06.2021	2019 01.06.2020	2017 28.05.2019
Afkastningsgrad	-100,3 %	-69,1 %	34,8 %	65,7 %	100,6 %
Dækningsgrad	Na.	Na.	Na.	Na.	Na.
Resultatgrad	Na.	Na.	Na.	Na.	Na.
Varelagerets omsætningshastighed	Na.	Na.	Na.	Na.	Na.
Egenkapitals-forretning	149,9 %	-210,7 %	33,6 %	78,8 %	100,0 %
Payout-ratio	Na.	Na.	Na.	83,2 %	Na.
Gældsdæknings-nøgletal	-357,9 %	-2.469,3 %	2.554,9 %	34.161,6 %	106.167,6 %
Soliditestgrad	-75,7 %	27,5 %	81,1 %	64,8 %	78,4 %
Likviditetsgrad	170,2 %	471,2 %	598,2 %	260,9 %	427,6 %

Resultat

14.06.2023

Gæld

14.06.2023

Årsrapport

14.06.2023

Nyeste:01.01.2022- 31.12.2022(offentliggjort: 14.06.2023)

Information om virksomhedens regnskabsklasse:The annual report of Embark Biotech ApS for 2022 has been prepared in accordance with the provisions in the Danish Financial Statements Act applying to reporting class B entities and elective choice of certain provisions applying to reporting class C entities.

Beretning

14.06.2023

Dato for ledelsens godkendelse af årsrapporten:2023-06-13

Beskrivelse af usædvanlige forhold, der kan have påvirket indregningen eller målingen:Going concern Embark Biotech is an early stage biotech Company and its research and development activities have historically been financed via license and collaboration agreements, loans, and capital injections or a combination of such. At 31 December 2022, the Company is financed via convertible loan. Until such time where the Company becomes able to generate positive cash-flows from its operations, additional funding is expected to be necessary to fund the Company's long term research and development activities. Management assess that the Company’s current net assets is sufficient to meet the Company's operational liquidity requirements at least through 31 December 2023. On this basis, the financial statements for 2022 are prepared on a going concern assumption.

Statement by Management on the annual report

Identifikation af den godkendte årsrapport:Today, the Board of Directors and the Executive Board have discussed and approved the annual report of Embark Biotech ApS for the financial year 1 January - 31 December 2022.

Management's review

Beskrivelse af virksomhedens væsentligste aktiviteter:Embark Biotech ApS was founded in 2017 and is a spin-out from the University of Copenhagen. The Company is a biotech start-up developing strategies for treating metabolic diseases and eating disorders. The technology platform is based on the pioneering work of Associate Professor Zachary Gerhart-Hines, Ph. D. and Jakob Bondo Hansen, Ph. D. within the field of adipose tissue biology and modulation of the axis between fat tissue and the brain. Our overall aim is to position Embark Biotech as the world-leading Company in adipose tissue biology, metabolism, and eating disorders. In Q3 2021 Embark Biotech became part of the BioInnovation Institute (BII) Creation House program and in connection with this received a convertible loan to advance the lead program further in development. In whole of 2022 Embark Biotech has been part of the Creation House program and has developed and matured the lead program even further.